Clinical development of anti-tuberculosis drugs

Clinical development of anti-tuberculosis drugs.

In the clinical development of new anti-tuberculosis drugs, the most important step is efficient Phase II studies to show whether the drug is likely to be able to shorten treatment and with what other drugs it has the greatest sterilizing activity. The use of non-linear mixed effects modelling applied to serial sputum cfu counts appears to be the most effective technique, but we know little abo...

Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.

Optimization of dosing strategies and companion drugs prior to Phase III trials is currently a critical obstacle in the development of new anti-tuberculosis drugs. Pharmacokinetic-pharmacodynamic (PK-PD) methods have assumed an important role in improving the efficiency of this process across the pharmaceutical industry and in other areas of anti-infective therapy. Information gained using PK-P...

Availability of anti-tuberculosis drugs in Europe.

Acknowledgements: The members of the SMIRA Group were: C. Piersimoni (Ospedali Riuniti, Ancona, Italy); P. Lorenzetti (Ospedale di Aosta, Aosta, Italy); D. Costa (Policlinico di Bari, Bari, Italy); A. Grimaldi (Ospedale Fallacara, Triggiano, Bari, Italy); M. Arosio and A. Goglio (Ospedali Riuniti, Bergamo, Italy); C. Mazza and L. Squintani (Ospedale Maggiore, Bologna, Italy); C. Larcher and E. ...

STUDY ON THE HEPATOTOXICITY OF ANTI-TUBERCULOSIS DRUGS IN 190 PATIE NTS WITH PULMONARY AND E XTRAPULMONARY TUBERCULOSIS

Tuberculosis is one of the oldest diseases that affects humans. The cause of this disease is Mycobacterium tuberculosis. This disease affects approximately 8.8 million people worldwide and led to over 3 million deaths in 1995. 95% of those affected and 98% of deaths occurred in developing countries. Hepatic reactions constitute a major proportion of drug reactions to antituberculosis drugs ...

drug-resistant tuberculosis and group 5 anti-tuberculosis drugs